Announcements
- Karolinska Developments årsstämma 2024
- Karolinska Development’s Annual General Meeting 2024
- Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition inleder andra delen av bolagets fas 1b/2-studie i PBC
- Delårsrapport för januari – mars 2024
- Interim Report - January-March 2024
- Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma
- Notice of Annual General Meeting in Karolinska Development AB (publ)
- Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC
- Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 267.52m |
Free float | 94.80m |
P/E (TTM) | 12.65 |
Market cap | 421.62m SEK |
EPS (TTM) | 0.1245 SEK |
Data delayed at least 15 minutes.
More ▼